杭州成喆生物医药

Chengzhe Biopharma is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapies for metabolic and cardiovascular diseases. The company's lead candidate, CZ-011, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). Chengzhe Biopharma leverages its expertise in medicinal chemistry and metabolic biology to address significant unmet medical needs in chronic liver disease, obesity, and dyslipidemia. The company is backed by prominent venture capital firms, including Qiming Venture Partners and TF Capital, and aims to develop best-in-class treatments for the global market.